Director equity awards detailed at Ascentage Pharma Group (AAPG)

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended insider ownership report for director Debra Yu, updating previously reported equity awards. The amendment shows stock options over 17,965 Ordinary Shares with an exercise price of 8.1400 per share and an expiration date of November 26, 2035. These options vest in twelve equal monthly tranches on the 26th of each month starting November 26, 2025. It also reports 27,965 restricted share units, each representing one Ordinary Share that vests in four equal installments on November 26 of 2026, 2027, 2028 and 2029. A footnote states the number of share options and/or vesting was inadvertently reported incorrectly in the original submission.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yu Debra

(Last) (First) (Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/26/2035	Ordinary Shares	17,965(4)	$8.14(2)	D
Restricted share units	(3)	(3)	Ordinary Shares	27,965(4)	$0	D

Explanation of Responses:

1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

4. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

Remarks:

	/Debra Yu/	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Debra Yu report in the amended Form 3/A for AAPG?

Debra Yu reports updated equity holdings in stock options and RSUs tied to ASCENTAGE PHARMA GROUP INTERNATIONAL Ordinary Shares. The amendment corrects prior disclosure of the number of options and/or vesting terms originally reported.

How many stock options over Ascentage Pharma (AAPG) shares are reported?

The amended report shows options over 17,965 Ordinary Shares with an exercise price of 8.1400 per share. These options vest in twelve equal tranches on the 26th of each month starting November 26, 2025.

What restricted share unit (RSU) holdings are disclosed for AAPG?

The amendment discloses 27,965 restricted share units, each representing one Ordinary Share of ASCENTAGE PHARMA GROUP INTERNATIONAL. These RSUs vest in four equal increments on November 26 of 2026, 2027, 2028 and 2029, subject to standard vesting conditions.

Why was the original Form 3 for ASCENTAGE PHARMA amended?

A footnote explains that the number of share options and/or vesting was inadvertently reported incorrectly in the original submission. The amended Form 3/A updates the correct equity award amounts and vesting schedule for director Debra Yu.

How is the stock option exercise price for AAPG calculated in this report?

The stock option exercise price is set in Hong Kong dollars (HKD), but the table shows 8.1400 per share as a USD conversion. This reflects the HKD price translated using the exchange rate on the original grant date.

What do the RSUs reported for AAPG represent for the holder?

Each RSU represents a contingent right to receive one Ordinary Share of ASCENTAGE PHARMA GROUP INTERNATIONAL upon vesting. Vesting occurs in four equal annual installments between 2026 and 2029, aligning compensation with long-term company performance.